Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding of Daily Subcutaneous Semaglutide in T2D
NCT02461589Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2015
- Primary completion
- Oct 2016
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) (13 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Glycosylated Haemoglobin at Week 26. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02461589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461589.